BiondVax Pharmaceuticals Ltd.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of BiondVax Pharmaceuticals Ltd. generated cash of -$7,265,000, which is more than the previous year. Cash used in financing activities reached the amount of $6,776,000 last year. Net change in cash is therefore -$3,302,000.
Cash Flow
| 2013 | -4.20M | 2.02M | 9.24M |
|---|---|---|---|
| 2014 | -7.57M | -180K | -782K |
| 2015 | -10.26M | -43K | 33.75M |
| 2016 | -9.65M | -7.81M | 0 |
| 2017 | -10.05M | 6.75M | 61.83M |
| 2018 | -57.19M | -23.45M | 84.32M |
| 2019 | -77.05M | -7.19M | 85.21M |
| 2020 | -72.53M | -5.93M | 13.71M |
| 2021 | -24.48M | -361K | 67.78M |
| 2022 | -7.26M | -836K | 6.77M |
BVXV Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 17.51M | 9.42M | 72.46M | 75.88M | 71.38M | 15.70M | 33.47M | 9.61M | 17.86M | 11.02M |
Operating activities | ||||||||||
Net income | -5.79M | -39.97M | -4.45M | -109.19M | -87.72M | -34.55M | -9.18M | -10.19M | -7.76M | -8.03M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 562K | 2.41M | 2.43M | 1.64M | 260K | 440K | 621K | 628K | 677K | 709K |
Stock-based compensation expense | 1.60M | 8.90M | 9.47M | 3.68M | 260K | 519K | 1.26M | 745K | 363K | 562K |
| Deferred income tax benefit | 1.60M | 8.90M | 9.47M | 3.68M | 260K | 519K | 1.26M | 745K | 363K | 562K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -175K | 1.23M | -15.19M | -3.66M | 14.5M | 5.53M | -238K | 415K | 132K | -12K |
Cash generated by operating activities | -7.26M | -24.48M | -72.53M | -77.05M | -57.19M | -10.05M | -9.65M | -10.26M | -7.57M | -4.20M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -836K | -430K | -6.13M | -7.42M | -23.73M | -4.50M | -20K | -34K | -30K | -196K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -836K | -361K | -5.93M | -7.19M | -23.45M | 6.75M | -7.81M | -43K | -180K | 2.02M |
Financing activities | ||||||||||
Common Stock Issued | 932K | 69.00M | 0 | 70.27M | 0 | 55.69M | 0 | 27.32M | 0 | 9.24M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -1.22M | -1.24M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 6.77M | 67.78M | 13.71M | 85.21M | 84.32M | 61.83M | 0 | 33.75M | -782K | 9.24M |
Net Change In Cash | -3.30M | 44.61M | -63.04M | -3.41M | 4.50M | 55.67M | -17.76M | 23.85M | -8.25M | 6.83M |
Cash at end of period | 14.21M | 54.03M | 9.42M | 72.46M | 75.88M | 71.38M | 15.70M | 33.47M | 9.61M | 17.86M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |